first-line biologic：IFX

PreclinicalSmall molecule

first-line biologic：IFX is one of 38 small molecule programs targeting Ulcerative Colitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ulcerative ColitisActive, not recruiting

Ulcerative ColitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

460 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Omvoh

Eli Lilly

Phase 3

14 2

Velsipity

Pfizer

Phase 3

11 3

Jyseleca

Gilead

Phase 3

6 4

Mesalazine

Ferring

Phase 3

17 5

Adtralza

LEO Pharma

Phase 3

1 6

Deltavit

HHyundai Pharmaceutical Co., LTD.

JNJ-42756493

Simponi

15 9

Remicade

Humira

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ulcerative Colitis1 trial

Selection and Efficacy-Influencing Factors of First-Line Biologic Agents in Moderate-to-Severe Ulcerative Colitis

Recruiting·XXijing Hospital of Digestive Diseases··NCT06962020·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for first-line biologic：IFX. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — first-line biologic：IFX compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for first-line biologic：IFX. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xijing Hospital of Digestive Diseases company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: XXijing Hospital of Digestive Diseases

first-line biologic：IFX

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ulcerative Colitis1 trial

References

Drug Info

Quick Facts

Related News